After escaping a clinical hold several years back, Dyne Therapeutics has revealed new phase 1/2 data for its Duchenne muscular dystrophy (DMD) therapy DYNE-251. The readout notes several serious ...
Upgrading Dyne Therapeutics to 'Buy' due to promising late-stage DM1 and DMD drug candidates and significant unmet need in both indications. Recent management changes and a more measured clinical ...
Hosted on MSN
Dyne Therapeutics Stock Drops After ‘Surprise’ Pivot In Primary Endpoint For Muscle Drug Trial
Shares of Dyne Therapeutics fell on Tuesday after the company revised the primary endpoint in the registrational expansion cohort of its Achieve trial for DYNE-101, a treatment for myotonic dystrophy ...
Dyne Therapeutics is a clinical-stage biotech. The company focuses on rare genetic disorders. It has seven programs in its pipeline, but only two are in clinical trials. Dyne focuses on treating ...
To continue reading this content, please enable JavaScript in your browser settings and refresh this page. Preview this article 1 min Joshua Brumm is stepping down as ...
Shares of Dyne Therapeutics declined after the company commenced an underwritten public offering and said it had secured up to $275 million of debt financing. The stock fell 9.8% to $8.59 on Monday.
To continue reading this content, please enable JavaScript in your browser settings and refresh this page. Preview this article 1 min In the past week, bluebird bio ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback